Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2014

View Archived Issues

Agilis and Intrexon collaborate on DNA-based therapeutics for Friedreich's ataxia

Oprozomib shows antitumor activity in phase I/II trials in patients with hematologic malignancies

TD-6450 demonstrates improved potency against genotype 1a-resistant mutants

Karyopharm presents results from phase I study of selinexor in hematological cancers

Meiji Seika Pharma begins phase II study of ME-1111

ASTX-727 demonstrates promising preclinical pharmacokinetic profile

ProNAi Therapeutics presents promising phase II data for PNT-2258

Japanese researchers prepare new agents for diabetes and other metabolic disorders

Janssen R&D Ireland patents novel agents for RSV infection

Novel neprilysin inhibitor prodrugs disclosed by Theravance

Georgia State University divulges novel agents for bacterial infections

Cerenis reports topline data for CER-001

Eisai launches Fycompa for partial-onset seizures in patients with epilepsy

IRM synthesizes novel EGFR inhibitors for cancer

NPS Pharmaceuticals begins registration study of teduglutide in pediatric patients

Horizon-labeled Vimovo now available in the U.S.

Incyte presents interim phase II results for INCB-039110 in patients with primary myelofibrosis

Marina Biotech and Mirna Therapeutics amend agreement for microRNA therapeutics

GlaxoSmithKline presents early clinical data for afuresertib

Sanofi presents phase II data for SAR-3419 and rituximab combination in B-cell lymphoma

Probiodrug transfers CDK9 inhibitor program to AstraZeneca

Salix Pharmaceuticals completes acquisition of Santarus

Enrollment open in phase IIa study of THR-18 in stroke patients treated with tPA

Sanofi expands access to data from clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...